We conclude that the PAC anti-oral cancer properties were controlled by impairing pro-survival signaling pathways and activating apoptosis pathways such as ERK1/2 activation, but not MEK1/2, AKT activation, NF-κB35,36,37 and β-catenin38, known to be implicated in tumor progression and as well for their resistance to chemo- and radiotherapy in several cancer types. This evidence concerns the gene MAPK3 and cancer.